Alumis Inc. $ALMS Shares Acquired by Octagon Capital Advisors LP

Octagon Capital Advisors LP increased its holdings in Alumis Inc. (NASDAQ:ALMS) by 11.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,830,700 shares of the company’s stock after purchasing an additional 300,000 shares during the period. Alumis makes up 6.9% of Octagon Capital Advisors LP’s investment portfolio, making the stock its 4th biggest holding. Octagon Capital Advisors LP’s holdings in Alumis were worth $62,360,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Ieq Capital LLC raised its holdings in Alumis by 4.1% during the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after buying an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after buying an additional 979 shares during the last quarter. Strs Ohio boosted its stake in shares of Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Alumis by 12.4% during the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after acquiring an additional 1,618 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of Alumis during the 1st quarter valued at about $42,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALMS. Guggenheim raised their price objective on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. HC Wainwright lowered shares of Alumis from a “buy” rating to a “neutral” rating and set a $25.00 price target on the stock. in a research report on Friday, May 15th. Oppenheimer lifted their price target on shares of Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Finally, Chardan Capital boosted their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alumis has an average rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Price Performance

ALMS opened at $28.00 on Monday. The firm has a market capitalization of $3.57 billion, a P/E ratio of -14.14 and a beta of -0.73. The stock’s 50 day moving average price is $24.50 and its two-hundred day moving average price is $24.84. Alumis Inc. has a 12-month low of $3.75 and a 12-month high of $31.35.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. As a group, analysts anticipate that Alumis Inc. will post -2.87 earnings per share for the current year.

Insider Transactions at Alumis

In related news, insider Sanam Pangali sold 5,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $28.00, for a total transaction of $140,000.00. Following the transaction, the insider owned 11,111 shares of the company’s stock, valued at approximately $311,108. The trade was a 31.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 33.70% of the company’s stock.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.